…, P Montan, U Stenevi, M Kugelberg… - Journal of Cataract & …, 2011 - Elsevier This review summarizes data collected by the Swedish National Cataract Register, which now contains data pertaining to more than a million cataract surgery procedures, representing 95.6% of the surgeries performed in Sweden during 1992−2009. During this period, the ...
M Lundström, A Behndig, M Kugelberg… - Journal of Cataract & …, 2011 - Elsevier The analyses were based on 602 553 cataract extractions reported to the NCR. A capsule complication was reported in 12 574 cataract extractions, corresponding to a frequency of 2.09%. The incidence of this complication consistently decreased each year from 2002 to 2006, after which it ...
K Mollazadegan, M Kugelberg… - American Journal of …, 2011 - Oxford Univ Press Vitamin deficiencies are prevalent in celiac disease (CD) and are associated with cataract formation, but it is unknown whether persons with CD are at increased risk of cataract. The authors' objective in this population-based cohort study was to determine the risk of ... Cited by 1 - Related articles - All 3 versions
…, M Lundström, M Kugelberg - Ophthalmology, 2011 - Elsevier The patients completed the Catquest questionnaire before and 6 months postoperatively. The 9 questions in the revised Catquest-9SF were selected from the Catquest and recoded by Rasch analysis, which makes it possible to use parametric statistics when analyzing the study ... Related articles - All 2 versions
…, F Bengtsson, J Ahlner, FC Kugelberg - Forensic Science …, 2011 - Elsevier Venlafaxine (VEN) is an antidepressant drug mainly metabolized by the cytochrome P450 (CYP) enzyme CYP2D6 to the active metabolite O-desmethylvenlafaxine (ODV). VEN is also metabolized to N-desmetylvenlafaxine (NDV) via CYP3A4. ODV and NDV are further ...
A Welander, KG Prütz, M Fored… - Gut, 2011 - gut.bmj.com Contributors AW, main investigator and wrote the first draft of the manuscript; KGP, acquisition of data and critical revision of the manuscript; MF, study concept and design, analysis and interpretation of the data, critical revision of the manuscript; JFL, study concept and design, supervision ...
J Berniac, T Bowser, M Draper… - US Patent …, 2011 - freepatentsonline.com ... The onset of weakness is usually recognized some time between 6 and 18 months. Juvenile SMA (SMA type 3 or Kugelberg-Welanderdisease) affects children generally older than 18 months. These children are able to walk at some time. ... Cached
J Berniac, T Bowser, M Draper, SB Levy… - US Patent …, 2011 - Google Patents ... The onset of weakness is usually recognized some time between 6 and 18 months. Juvenile SMA (SMA type 3 or Kugelberg-Welanderdisease) affects children generally older 40 than 18 months. These children are able to walk at some time. ... Related articles - All 3 versions
D Corkin… - Care Planning in Children and Young …, 2012 - books.google.com ... Muscular Atrophy 345 • Most severe • Diagnosis before three months of age • Diagnosis made before two years of age Type I SMA (Werdnig- Hoffman disease) Type II SMA (moderate) Type IV SMA (adult form) Type III SMA (Kugelberg- Welanderdisease)• Relatively mild ...
J Palmio, S Sandell, T Suominen, S Penttilä… - Neuromuscular …, 2011 - Elsevier ... Haplotype genotyping for the founder mutation haplotypes of Finnish TMD on chromosome 2q31 and the Nordic Welanderdisease locus on 2p13 were performed. ... These characteristics are typical both for titin mutated TMD disease and 2p13 linked Welander distal myopathy. ... Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
